IL316218A - Preparations and methods for treating eye diseases - Google Patents

Preparations and methods for treating eye diseases

Info

Publication number
IL316218A
IL316218A IL316218A IL31621824A IL316218A IL 316218 A IL316218 A IL 316218A IL 316218 A IL316218 A IL 316218A IL 31621824 A IL31621824 A IL 31621824A IL 316218 A IL316218 A IL 316218A
Authority
IL
Israel
Prior art keywords
hvr
seq
amino acid
antibody
comprises administering
Prior art date
Application number
IL316218A
Other languages
English (en)
Hebrew (he)
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of IL316218A publication Critical patent/IL316218A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL316218A 2022-04-29 2023-04-28 Preparations and methods for treating eye diseases IL316218A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263336539P 2022-04-29 2022-04-29
PCT/US2023/066393 WO2023212719A1 (en) 2022-04-29 2023-04-28 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
IL316218A true IL316218A (en) 2024-12-01

Family

ID=88519880

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316218A IL316218A (en) 2022-04-29 2023-04-28 Preparations and methods for treating eye diseases

Country Status (10)

Country Link
US (1) US20250313614A1 (enExample)
EP (1) EP4518896A4 (enExample)
JP (1) JP2025515485A (enExample)
KR (1) KR20250006238A (enExample)
CN (1) CN119136830A (enExample)
AU (1) AU2023262202A1 (enExample)
CA (1) CA3250843A1 (enExample)
IL (1) IL316218A (enExample)
MX (1) MX2024013326A (enExample)
WO (1) WO2023212719A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184235A1 (en) * 2024-02-28 2025-09-04 Onl Therapeutics, Inc. Methods and compositions for treating glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CN116782940A (zh) * 2020-12-04 2023-09-19 安尼艾克松股份有限公司 用于治疗眼部疾病的组合物和方法

Also Published As

Publication number Publication date
AU2023262202A1 (en) 2024-10-24
KR20250006238A (ko) 2025-01-10
US20250313614A1 (en) 2025-10-09
JP2025515485A (ja) 2025-05-15
WO2023212719A1 (en) 2023-11-02
CN119136830A (zh) 2024-12-13
EP4518896A1 (en) 2025-03-12
EP4518896A4 (en) 2026-08-12
CA3250843A1 (en) 2023-11-02
MX2024013326A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
JP2011506483A5 (enExample)
JP2017534646A5 (enExample)
JP2023517236A5 (enExample)
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
JP2017515811A5 (enExample)
HRP20201493T1 (hr) Anti-alfa-sinukleinska protutijela i postupci uporabe
JP2018108086A5 (enExample)
JP2022548947A5 (enExample)
RU2018119014A (ru) АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
CA2707400A1 (en) Method for treating bone fracture with anti-sclerostin antibodies
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2019502712A5 (enExample)
JP2017522861A5 (enExample)
JP2015533795A5 (enExample)
JP2017537896A5 (enExample)
JP2017536102A5 (enExample)
IL272674B2 (en) Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation
JP2017534645A5 (enExample)
JP2024531151A5 (enExample)
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
JP2019513726A5 (enExample)
RU2014109093A (ru) Антитела против нейрегулина и их применение
JP2023542291A5 (enExample)
JP2023551734A5 (enExample)